Prosecution Insights
Prosecution Insights
5 pending office actions • 3 clients • 5 examiners • 5 art units • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| No statute on record | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESPINOSA, CLAUDIA EDILMA | 1 | 53.2% | +58.5% |
| GATES, BRADFORD M | 1 | 74.5% | +24.2% |
| SCHNIREL, ANDREW B | 1 | 50.4% | -6.1% |
| NIEBAUER, RONALD T | 1 | 41.4% | +33.8% |
| EVANS, CHRISTOPHER RYAN | 1 | 58.8% | +70.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19204171 | CHEMOTHERAPEUTIC PACLITAXEL BASED MICELLULAR NANOPARTICLES | ESPINOSA, CLAUDIA EDILMA | 73d overdue |
| 18041289 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | NIEBAUER, RONALD T | 44d overdue |
| 17637018 | HIGH-BRIGHTNESS FLUOROPHORES FOR QUANTIFICATION AND PHENOTYPING OF EXTRACELLULAR VESICLES | EVANS, CHRISTOPHER RYAN | 8d overdue |
| 18847313 | METHOD OF MAKING BORON NITRIDE NANOTUBES AND REACTION CHAMBER THEREFORE | GATES, BRADFORD M | 71d |
| Client (Assignee) | Pending OAs |
|---|---|
| Peptinovo Biopharma Inc. | 2 |
| Michigan Tech | 2 |
| Optique Debt Investment, LLC | 1 |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1713 | 1 |
| 2625 | 1 |
| 1658 | 1 |
| 1677 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19204171 | CHEMOTHERAPEUTIC PACLITAXEL BASED MICELLULAR NANOPARTICLES | Peptinovo Biopharma, Inc. | ESPINOSA, CLAUDIA EDILMA | 1654 | Other | Non-Final OA | 73d overdue | Pending | May 09, 2025 |
| 18847313 | METHOD OF MAKING BORON NITRIDE NANOTUBES AND REACTION CHAMBER THEREFORE | Michigan Technological University | GATES, BRADFORD M | 1713 | §112 | Final Rejection | 71d | Pending | Sep 16, 2024 |
| 18758379 | HYBRID REFLECTIVE/REFRACTIVE HEAD MOUNTED DISPLAY | Optique Debt Investment, LLC | SCHNIREL, ANDREW B | 2625 | §103 | Non-Final OA | 4d overdue | Pending | Jun 28, 2024 |
| 18041289 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | Peptinovo Biopharma, Inc. | NIEBAUER, RONALD T | 1658 | Other | Non-Final OA | 44d overdue | Pending | Feb 10, 2023 |
| 17637018 | HIGH-BRIGHTNESS FLUOROPHORES FOR QUANTIFICATION AND PHENOTYPING OF EXTRACELLULAR VESICLES | Michigan Technological University | EVANS, CHRISTOPHER RYAN | 1677 | Other | Non-Final OA | 8d overdue | Pending | Feb 21, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial